Your session is about to expire
← Back to Search
pepinemab + pembrolizumab for Head and Neck Squamous Cell Carcinoma (KEYNOTE-B84 Trial)
KEYNOTE-B84 Trial Summary
This trial will test if the combination of two immunotherapy drugs is safe and tolerable for people with R/M HNSCC.
KEYNOTE-B84 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowKEYNOTE-B84 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.KEYNOTE-B84 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants are being sought for this research study?
"In order to reach statistical significance, this clinical trial requires 65 patients that match the inclusion criteria. The sponsor, Vaccinex Inc., has chosen Siteman Cancer Center - Washington University Medical Campus and Virginia Cancer Specialists - Fairfax as two of their many study locations."
What other similar drugs have been studied in coordination with pepinemab and pembrolizumab?
"As of now, 1005 different clinical trials are investigating pepinemab + pembrolizumab. Furthermore, 122 of these studies have reached Phase 3. Many of the active trials for this combination therapy are running out of in Houston, Texas; however, there are 36068 locations total running studies for pepinemab + pembrolizumab."
Is this research project still looking for participants?
"The trial you are inquiring about, as per the most recent information available on clinicaltrials.gov, is still recruiting patients. This particular study was first posted on 8/9/2021 and was last edited on 6/13/2022."
Are there any restrictions for who can participate in this research?
"Researchers are looking for 65 individuals that have been diagnosed with hnscc. The age bracket for this study is 18-100 years old. Candidates must also meet the following prerequisites: RECIST 1.1, life expectancy of 12 weeks, ECOG PS 0 or 1, and more as specified in the original answer."
Is this clinical trial only accepting people who are over 60 years old?
"The age range for this particular trial is 18 to 100 years old. Out of the 4703 total clinical trials, 263 are for patients that fall below the age of eighteen and 4440 are for people aged 65 or older."
What are the goals of this medical experiment?
"The primary focus of this long-term study is to establish the Recommended Phase 2 Dose (RP2D) of the medication. Additionally, researchers will be measuring secondary objectives like the Extent of Disease, Overall Survival rates, and Duration of Response in order to collect a more comprehensive data set."
In how many distinct places is this research being conducted?
"Washington University Medical Campus in Saint Louis, Missouri; Virginia Cancer Specialists - Fairfax in Fairfax, Virginia; Hematology/Oncology Clinic-Baton Rouge in Baton Rouge, Louisiana are all Siteman Cancer Center locations where patients can be enrolled for this study. There are 17 other potential sites as well."
Share this study with friends
Copy Link
Messenger